Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Prevalence of Generalized myasthenia gravis
8 evidence topics · 8 sources
United States, 2021 claims and electronic health records: diagnosed prevalence of all myasthenia gravis
“The diagnosed prevalence and incidence of MG in the United States in 2021 were calculated to be 37.0 per 100,000 persons and 3.1 per 100,000 persons, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The updated prevalence and incidence of MG in the United States in 2021 are higher than previous reports from the 1980s and early 2000s, following a global trend of increased prevalence and incidence for this disorder in the last few decades.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States, 2017 claims and 2021 extrapolation: prevalence and number of adults with all myasthenia gravis
“Using a previously validated algorithm, we identified cases of MG in two Truven Health MarketScan databases, which during 2017 included a sample of approximately 20 million commercially insured and Medicare recipients, plus 10 million Medicaid recipients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From the US commercially/Medicare-insured cohort, we calculated an age-and sex-standardized incidence of 68.5 new cases per million person-years with an adjusted prevalence of 316.4 per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within the Medicaid-insured population, similar yet slightly lower numbers emerged: the adjusted incidence was 49.7 new cases per million person-years, and the adjusted prevalence rate was 203.7 cases per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given our results, we were able to estimate that there were approximately 82,715 US adults living with MG in 2021 (or an estimated 320.2 cases per million adults in the USA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States, Medicare fee-for-service beneficiaries aged 65 years and older: prevalence of all myasthenia gravis, 2006 to 2019
“The period prevalence of MG increased from 81 to 119 per 100,000 FFS A/B population from 2006–2007 to 2018–2019 (p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing trends of prevalence were observed in all sex (male/female), age (65–69/70–74/75–79/80+), race/ethnic (African American/Asian/Hispanics of any race/non-Hispanic White/other), and census region (Northeast/Midwest/South/West) subgroups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global meta-analysis of 63 studies: prevalence of all myasthenia gravis
“After deleting articles unrelated to the research question, finally, 63 articles with a sample size of 1,206,961,907 people were included in the meta-analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of MG worldwide was estimated to be 12.4 people (95% CI 10.6–14.5) per 100,000 population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“which has the highest prevalence in the Americas with 19 people (95% CI 15–23.8)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global systematic review of studies through February 2024: prevalence of all myasthenia gravis
“Prevalence of MG ranged from 20 to 475 cases per million, with a mean prevalence of 173.3 (95% confidence interval [CI]: 129.7–215.5) cases per million and a median prevalence of 129.6 cases per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean PR was 97.5 (95% CI: 59.9–141.9; range: 20–174.2) cases per million considering studies from 1952 to 2007 (the most recent period investigated by the last systematic review [7]), while the mean PR increased up to 220.1 (95% CI: 149.3–288.1; range: 78–475) cases per million considering the period 2008–2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“North America showed a mean PR of 341.4 (range: 142–475) cases per million” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most of the included studies (81.9%) examined all types of MG (ALL MG), reporting prevalence (59 studies), incidence (50 studies), and mortality (16 studies).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global systematic review of studies from 1950 to 2007: pooled prevalence of all myasthenia gravis
“The observed PR ranged from 15 to 179 per million” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated pooled PR is 77.7 cases per million (C.I.: 63.98, 94.30) but, as for IR there was marked heterogeneity with I2 = 98% (C.I.: 97-98%) observed across studies limiting interpretation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Taiwan, 2009 to 2019: prevalence of generalized myasthenia gravis
“The number of patients with gMG increased from 1,576 in 2009 to 2,638 in 2019 and the mean (standard deviation) age from 51.63 (17.32) to 55.38 (16.29) years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of patients with gMG increased annually from 6.83/100,000 population in 2009 to 11.18/100,000 population in 2019 (p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The total number of patients with MG (ocular or generalized) increased from 3,647 in 2009 to 6,293 in 2019, with prevalence rates that increased annually from 15.80 per 100,000 population to 26.67 per 100,000 population, a 1.7-fold increase over the study period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote